Hjem › Mavekreft › Oregon › Portland
Kliniske studier for Mavekreft i Portland, OR
13 studier for Mavekreft søker deltakere på steder i og rundt Portland (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi unna
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
RekruttererFase 1
- Site 02, Portland
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
RekruttererFase 2/3
- Northwest Cancer Specialists, P.C., Portland
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
RekruttererFase 3
- Oregon Health and Science University, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Providence Portland Medical Center, Portland
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RekruttererFase 3
- Research Site, Portland
- Research Site, Portland
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekruttererFase 1
- Providence Cancer Institute, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
RekruttererFase 1
- Providence Cancer Institute, Portland
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
RekruttererFase 3
- Providence Portland Medical Center, Portland
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- Investigative Site #121, Portland
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekruttererFase 1
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- og 1 flere
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Oregon Health Sciences University, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Portland
Mavekreft-studier i andre byer
- Houston, TX42 studier
- Boston, MA32 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Baldwin Park, CA22 studier
- Los Angeles, CA22 studier
- Arlington, VA20 studier
- Dallas, TX19 studier
- San Antonio, TX19 studier
- St. Louis, MO18 studier
- Grand Rapids, MI18 studier
- Washington, DC16 studier
Andre studier i Portland
- Ikke-småcellet lungekreft46 studier
- Kreft (alle typer)34 studier
- Brystkreft33 studier
- Prostatakreft33 studier
- Metastatisk kreft29 studier
- Kolorektal kreft28 studier
- Eggstokkreft27 studier
- Lungekreft26 studier
- Akut myelogen leukemi25 studier
- Endometriekreft24 studier
- Plateepitelcancer i hode og hals19 studier
- Pankreaskreft19 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.